Treats chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated…. Sold as Vosevi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Sofosbuvir; Velpatasvir; Voxilaprevir (sold as Vosevi), first approved Jul 18, 2017, with 1 new use approved and 0 published complete response letters.
| Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA TreatmentHepatitis C Virus (HCV) · Xiangya Hospital of Central South University | — | Active, not recruiting | May 4, 2026 |
| Combating Related Epidemics in HCVHIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) · Duke University | Phase 4 | Not yet recruiting | Apr 30, 2026 |
| Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard StrategyHepatitis C Virus Infection · ANRS, Emerging Infectious Diseases | Phase 4 | Not yet recruiting | Aug 1, 2025 |
| The Efficacy of Vosevi in Treating DAA-experienced PatientsChronic Hepatitis C, Medication Reaction · The Third Affiliated Hospital of Guangzhou Medical University | — | Recruiting | Dec 22, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 18, 2017 | VoseviNDA 209195 · New molecular entity, new combination | Gilead Sciences Inc | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
